Upgrade to SI Premium - Free Trial

Truist Reiterates Buy Rating on Viridian Therapeutic (VRDN) Following Veligrotug's FDA approval

June 29, 2026 9:28 AM
Truist Securities analyst Greg Renza reiterated a Buy rating and $35.00 price target on Viridian Therapeutic (NASDAQ: VRDN).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles